Please Wait...

Fixing delays in study site activation: 3-Fold Solution

What's behind slow site activation?

Sean Stanton of Bioclinica Research provides meaningful insights on study site activation in his latest article, 'Improving Site Activation: Three-Fold Solution' published in ICT's August 2017 issue.

Having spent the last 25 years of his career focused on creating successful, high-performing research sites, Sean gives a candid look at site activation —   a rarely explored activity critical to laying the foundation for a successful study. To date, he's led the start-up of 25 trial sites, six inpatient hospitals and 19 outpatient clinics where more than 5,000 trials have been conducted leading to over 50 drug approvals.

From these experiences he shares, "Astonishingly, the same four problems that delayed trial start-ups 20 years ago are still doing so today; very little has changed." In the article Sean explores common trouble spots experienced by sponsors, CROs and investigator sites who consistently name redundant training and certification, budgeting and contracting issues, vendor relations and scheduling concerns as the top reasons why site activation can take up to a year. Certainly, these are not the only issues that cause stoppage. Feasibility studies, regulatory matters and institutional review board (IRB) approvals play their part.

With some adjustments in the site activation approach, stakeholders can turn this around. Sean looks at the root causes of delays and goes on to outline a three-fold solution to speed up trial start dates —  potentially reducing site activation times to as little as 30 days.

Get meaningful insights into site activation from Sean's unique perspective. Access the full article here and get practical first-hand advice and a solution that you can put into immediate action.

To consult with Sean or another Bioclinica expert, submit an online inquiry and we'll be in touch. And drop us a line anytime! We'd love to hear from you about what is, or is not, working for you in your clinical trials.

Category: 

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

Attending CBI's IRT conf? Catch 10/27 @bioclinica GSK talk on bens of sponsor controlled #IRT. Here's the core tech… https://t.co/zFiQswIQFb
bioclinica (10 hours ago)
RT @Xtalks: #Cardiovascular Imaging for Monitoring Safety: Visualizing Outcomes @bioclinica https://t.co/5osqBkDFKm
bioclinica (10 hours ago)
Want stellar imaging acquisition & assessment in your #clinicaltrial ? Get tips in @bioclinica 's Tim Crowe's blog https://t.co/hzbV3Cmlyc
bioclinica (Yesterday)
Will you be at CBI's IRT conference in Philly Oct 26-27? https://t.co/C7vuxwnCH7
bioclinica (Yesterday)
Must-see live webinar packed w info for those who want to learn about CV safety from the leading experts.… https://t.co/4y5OaUNeIk
bioclinica (5 days ago)
Right at home near our Princeton offc is where to catch us talking all things #RTSM Oct.18-19.… https://t.co/h1OSFwiSFi
bioclinica (5 days ago)

Latest Blogs: